The FDA wants to develop product-agnostic registries that could be external controls for diffuse midline glioma inclusive of diffuse intrinsic pontine glioma trials. (Shutterstock)
Learn what's happening at the US FDA. On the go.
Derrick Gingery and the team bring you a weekly "Drug Fix".
